These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 19493996)

  • 1. Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains.
    Pan C; Cai L; Lu H; Qi Z; Jiang S
    J Virol; 2009 Aug; 83(16):7862-72. PubMed ID: 19493996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions between different generation HIV-1 fusion inhibitors and the putative mechanism underlying the synergistic anti-HIV-1 effect resulting from their combination.
    Cai L; Pan C; Xu L; Shui Y; Liu K; Jiang S
    FASEB J; 2012 Mar; 26(3):1018-26. PubMed ID: 22085645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection of T1249-resistant human immunodeficiency virus type 1 variants.
    Eggink D; Baldwin CE; Deng Y; Langedijk JP; Lu M; Sanders RW; Berkhout B
    J Virol; 2008 Jul; 82(13):6678-88. PubMed ID: 18434391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains.
    He Y; Cheng J; Lu H; Li J; Hu J; Qi Z; Liu Z; Jiang S; Dai Q
    Proc Natl Acad Sci U S A; 2008 Oct; 105(42):16332-7. PubMed ID: 18852475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain.
    Lu L; Tong P; Yu X; Pan C; Zou P; Chen YH; Jiang S
    Biochim Biophys Acta; 2012 Dec; 1818(12):2950-7. PubMed ID: 22867851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus.
    Zhu Y; Zhang X; Ding X; Chong H; Cui S; He J; Wang X; He Y
    J Biol Chem; 2018 Apr; 293(14):5323-5334. PubMed ID: 29425101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors.
    Pan C; Lu H; Qi Z; Jiang S
    AIDS; 2009 Mar; 23(5):639-41. PubMed ID: 19242316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel chimeric protein-based HIV-1 fusion inhibitor targeting gp41 glycoprotein with high potency and stability.
    Pan C; Cai L; Lu H; Lu L; Jiang S
    J Biol Chem; 2011 Aug; 286(32):28425-34. PubMed ID: 21690094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy.
    Zhu X; Zhu Y; Ye S; Wang Q; Xu W; Su S; Sun Z; Yu F; Liu Q; Wang C; Zhang T; Zhang Z; Zhang X; Xu J; Du L; Liu K; Lu L; Zhang R; Jiang S
    Sci Rep; 2015 Aug; 5():13028. PubMed ID: 26286358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.
    Champagne K; Shishido A; Root MJ
    J Biol Chem; 2009 Feb; 284(6):3619-27. PubMed ID: 19073602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.
    Cai L; Gochin M; Liu K
    Curr Top Med Chem; 2011 Dec; 11(24):2959-84. PubMed ID: 22044229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Revisiting the mechanism of enfuvirtide and designing an analog with improved fusion inhibitory activity by targeting triple sites in gp41.
    Xu W; Pu J; Su S; Hua C; Su X; Wang Q; Jiang S; Lu L
    AIDS; 2019 Aug; 33(10):1545-1555. PubMed ID: 30932963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors.
    Eggink D; Langedijk JP; Bonvin AM; Deng Y; Lu M; Berkhout B; Sanders RW
    J Biol Chem; 2009 Sep; 284(39):26941-50. PubMed ID: 19617355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
    Xiong S; Borrego P; Ding X; Zhu Y; Martins A; Chong H; Taveira N; He Y
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesized peptide inhibitors of HIV-1 gp41-dependent membrane fusion.
    He Y
    Curr Pharm Des; 2013; 19(10):1800-9. PubMed ID: 23092277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition.
    Ding X; Zhang X; Chong H; Zhu Y; Wei H; Wu X; He J; Wang X; He Y
    J Virol; 2017 Sep; 91(18):. PubMed ID: 28659478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor.
    Chong H; Yao X; Zhang C; Cai L; Cui S; Wang Y; He Y
    PLoS One; 2012; 7(3):e32599. PubMed ID: 22403678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
    Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket.
    Su Y; Chong H; Qiu Z; Xiong S; He Y
    J Virol; 2015 Jun; 89(11):5801-11. PubMed ID: 25787278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human immunodeficiency virus type 1 variants resistant to first- and second-version fusion inhibitors and cytopathic in ex vivo human lymphoid tissue.
    Chinnadurai R; Rajan D; Münch J; Kirchhoff F
    J Virol; 2007 Jun; 81(12):6563-72. PubMed ID: 17428857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.